Section 32

Portfolio Co Investors 2026 for Section 32: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Section 32 accounts for 31 tracked companies with verified cap-table data, 31 of which disclose round sizes totalling $4.8B. The median disclosed raise is $100M, and the largest is EQRx at $750M, ahead of NewLimit ($682M) and Dialpad ($450M).

The names that recur most often on these co-invested cap tables are Section 32 (31 companies), Casdin Capital (7 companies), Andreessen Horowitz (5 companies), Alexandria Venture Investments (4 companies), GV (3 companies), ARCH Venture Partners (3 companies). By latest disclosed round, the market skews Series B (18), Series A (5), Series C (4), Series F (1).

Best funded Section 32 companies

  1. EQRx — $750M (latest: Series B)
  2. NewLimit — $682M (latest: Series C)
  3. Dialpad — $450M (latest: Series F)
  4. Thrive Earlier Detection — $367M (latest: Series B)
  5. Metromile — $282M (latest: Series E)
  6. ROME Therapeutics — $199M (latest: Series B)
  7. Autobahn Therapeutics — $176M (latest: Series B)
  8. Celsius Therapeutics — $148M (latest: Series B)
  9. Cyclewell — $132M (latest: Series B)
  10. BigHat Biosciences — $130M
  11. Character Biosciences — $128M (latest: Series B)
  12. Nested Therapeutics — $125M (latest: Series A)
  13. Phaidra — $120M (latest: Series B)
  14. Forward Networks — $112M (latest: Series D)
  15. Satellite Bio — $110M (latest: Series A)

Section 32 — related firms and companies (56)

Section 32 profile · All research reports